Ductal, intraductal, and cribriform carcinoma of the prostate : Molecular characteristics and clinical management
Copyright © 2024 Elsevier Inc. All rights reserved..
Prostatic acinar adenocarcinoma accounts for approximately 95% of prostate cancer (CaP) cases. The remaining 5% of histologic subtypes of CaP are known to be more aggressive and have recently garnered substantial attention. These histologic subtypes - namely, prostatic ductal adenocarcinoma (PDA), intraductal carcinoma of the prostate (IDC-P), and cribriform carcinoma of the prostate (CC-P) - typically exhibit distinct growth characteristics, genomic features, and unique oncologic outcomes. For example, PTEN mutations, which cause uncontrolled cell growth, are frequently present in IDC-P and CC-P. Germline mutations in homologous DNA recombination repair (HRR) genes (e.g., BRCA1, BRCA2, ATM, PALB2, and CHEK2) are discovered in 40% of patients with IDC-P, while only 9% of patients without ductal involvement had a germline mutation. CC-P is associated with deletions in common tumor suppressor genes, including PTEN, TP53, NKX3-1, MAP3K7, RB1, and CHD1. Evidence suggests abiraterone may be superior to docetaxel as a first-line treatment for patients with IDC-P. To address these and other critical pathological attributes, this review examines the molecular pathology, genetics, treatments, and oncologic outcomes associated with CC-P, PDA, and IDC-P with the objective of creating a comprehensive resource with a centralized repository of information on PDA, IDC-P, and CC-P.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Urologic oncology - 42(2024), 5 vom: 12. Apr., Seite 144-154 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shi, Yibo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.urolonc.2024.01.037 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369753356 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369753356 | ||
| 003 | DE-627 | ||
| 005 | 20240415233426.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.urolonc.2024.01.037 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM369753356 | ||
| 035 | |a (NLM)38485644 | ||
| 035 | |a (PII)S1078-1439(24)00053-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shi, Yibo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ductal, intraductal, and cribriform carcinoma of the prostate |b Molecular characteristics and clinical management |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a Prostatic acinar adenocarcinoma accounts for approximately 95% of prostate cancer (CaP) cases. The remaining 5% of histologic subtypes of CaP are known to be more aggressive and have recently garnered substantial attention. These histologic subtypes - namely, prostatic ductal adenocarcinoma (PDA), intraductal carcinoma of the prostate (IDC-P), and cribriform carcinoma of the prostate (CC-P) - typically exhibit distinct growth characteristics, genomic features, and unique oncologic outcomes. For example, PTEN mutations, which cause uncontrolled cell growth, are frequently present in IDC-P and CC-P. Germline mutations in homologous DNA recombination repair (HRR) genes (e.g., BRCA1, BRCA2, ATM, PALB2, and CHEK2) are discovered in 40% of patients with IDC-P, while only 9% of patients without ductal involvement had a germline mutation. CC-P is associated with deletions in common tumor suppressor genes, including PTEN, TP53, NKX3-1, MAP3K7, RB1, and CHD1. Evidence suggests abiraterone may be superior to docetaxel as a first-line treatment for patients with IDC-P. To address these and other critical pathological attributes, this review examines the molecular pathology, genetics, treatments, and oncologic outcomes associated with CC-P, PDA, and IDC-P with the objective of creating a comprehensive resource with a centralized repository of information on PDA, IDC-P, and CC-P | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Clinical management | |
| 650 | 4 | |a Cribriform carcinoma | |
| 650 | 4 | |a Intraductal carcinoma | |
| 650 | 4 | |a Molecular pathology | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a Prostatic ductal adenocarcinoma | |
| 700 | 1 | |a Wang, Hanzhang |e verfasserin |4 aut | |
| 700 | 1 | |a Golijanin, Borivoj |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Sikov, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Hyams, Elias |e verfasserin |4 aut | |
| 700 | 1 | |a Pareek, Gyan |e verfasserin |4 aut | |
| 700 | 1 | |a Carneiro, Benedito A |e verfasserin |4 aut | |
| 700 | 1 | |a Mega, Anthony E |e verfasserin |4 aut | |
| 700 | 1 | |a Lagos, Galina G |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lisha |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhiping |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Liang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urologic oncology |d 1995 |g 42(2024), 5 vom: 12. Apr., Seite 144-154 |w (DE-627)NLM097435058 |x 1873-2496 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:5 |g day:12 |g month:04 |g pages:144-154 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.urolonc.2024.01.037 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 5 |b 12 |c 04 |h 144-154 | ||